Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model

Date

21 Oct 2023

Session

Poster session 09

Topics

Translational Research;  Immunotherapy;  Basic Science

Tumour Site

Colon and Rectal Cancer

Presenters

Olga Rakitina

Citation

Annals of Oncology (2023) 34 (suppl_2): S187-S214. 10.1016/S0923-7534(23)01931-2

Authors

O. Rakitina, A. Kuzmich, D. Didych, S. Kondrateva, O. Bezborodova, I. Alekseenko

Author affiliations

  • Group Of Gene Immunooncotherapy, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, 117997 - Moscow/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 67P

Background

One way to significantly reduce the incidence of systemic side effects of antitumoral immunotherapeutics is intratumoral gene-immune therapy. The use of non-viral systems is attractive for gene therapy due to low immunogenicity of the carrier, low production costs, and relatively high capacity. Thus, non-viral intratumoral gene-immune therapy is a promising area for development of antitumor drugs. OX40 and 4-1BB T cell co-stimulators are popular targets in immunotherapeutic drug development, but currently there are no approved drugs targeting these receptors. We suppose that the natural ligands of these receptors, OX40L and 4-1BBL, would be effective in non-viral gene-immune therapeutics.

Methods

The antitumor effect of stable OX40L or 4-1BBL expression by inoculated cancer cells on CT26 tumor growth was studied. CT26 cell lines stably expressing OX40L or 4-1BBL were obtained, tumor graftability and growth in BALB/c mice were evaluated. Next, antitumor effect of non-viral gene-immune therapy with OX40L or 4-1BBL was studied, complexes of polymeric carrier with plasmid DNA encoding OX40L or 4-1BBL were prepared and injected three times into CT26wt subcutaneous tumors in BALB/c mice, starting when tumors reached 50±15 mm3 .

Results

Stable expression of OX40L and 4-1BBL significantly suppressed CT26 tumor growth, delayed tumor resorption was observed in the experimental groups. The use of OX40L and 4-1BBL in the context of gene-immune therapy had a significant effect on CT26 tumor growth – median animal survival compared to the control group was increased by 26.5% (OX40L) and 41.2% (4-1BBL), life expectancy was increased by 24% (OX40L) and 24.5% (4-1BBL), tumor growth inhibition 10 days after treatment was 70% (OX40L) and 71.3% (4-1BBL). No visible immune-related adverse events (irAEs) were observed.

Conclusions

OX40L and 4-1BBL have a comparable potent antitumoral effect on CT26 tumor growth in the context of non-viral gene-immune therapy, and such therapeutic approach does not yield visible systemic irAEs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Group of Gene Immuno Oncotherapy, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry.

Funding

This study was supported by RSF grant 22-25-00806, https://rscf.ru/project/22-25-00806/.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.